This study compares ingredients listed on the labels of cannabidiol products sold online to actual product constituents determined by laboratory analysis.
This study analyzed the dose accuracy of labels from edibile medical cannabis products dispensed in 3 US cities.
This commentary discusses a national survey study published in JAMA Psychiatry that found cannabis use within the general population is associated with an increased risk for substance use disorders.
Warner and coauthors conducted a retrospective cohort study of 44 612 physicians in anesthesiology residency programs to describe the incidence and outcomes of substance use disorder among a subset of US physicians.
This commentary discusses a cohort study published in JAMA Psychiatry that investigated associations between cannabis use over 20 years and physical health problems in midlife.
Saitz and coauthors tested the efficacy of 2 brief interventions among 528 adults with unhealthy drug use identified by screening in primary care. They compared a brief negotiated interview and an intervention based on motivational interviewing with no brief intervention. In an Editorial, Hingson and Compton discuss the importance of exploring drug use with patients in primary care.
A randomized trial involving opioid-dependent patients found that buprenorphine treatment with coordinated follow-up for ongoing treatment was more effective than referral with or without brief intervention.
This meta-analysis summarizes the effectiveness of cannabis and cannabinoids for managing medical and psychotic disorders, including chemotherapy-induced nausea and vomiting, chronic pain, and mood and sleep disorders.
This study used data from National Health Expenditure Accounts to estimate US spending on personal health care and public health, according to condition, age and sex group, and type of care.
You currently have no searches saved.